| Salmeron, Betty Jo |
NCT02927236: Theta-Burst Stimulation as a Treatment for Reducing Cocaine Use |
|
|
| Completed | 4 | 45 | US | TMS | National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder, Cocaine Dependence | 10/23 | 10/23 | | |
NCT01036685: Cognitive Task Development and Implementation for Functional MRI Studies |
|
|
| Recruiting | N/A | 750 | US | | National Institute on Drug Abuse (NIDA) | Drug Abuse, Nicotine Dependence | | | | |
NCT01148381: Characterization of Phenotypic and Genotypic Regressors for Imaging |
|
|
| Recruiting | N/A | 2625 | US | | National Institute on Drug Abuse (NIDA) | Healthy Volunteers, Substance Use Disorders | | | | |
| Recruiting | N/A | 70 | US | TMS (MagVenture MagPro 100 with MagOption) | National Institute on Drug Abuse (NIDA) | Healthy Volunteers | 12/26 | 12/26 | | |
NCT05669716: Adolescent Vaping Characterization and Parent Views on Adolescent Vaping Protocol |
|
|
| Recruiting | N/A | 1600 | US | | National Institute on Drug Abuse (NIDA) | Healthy Volunteers, Vaping Teens | 07/25 | 07/25 | | |
NCT01867411: Multimodal Neuroimaging Genetic Biomarkers of Nicotine AddictionSeverity |
|
|
| Completed | N/A | 159 | US | | National Institute on Drug Abuse (NIDA) | Nicotine Dependence | 06/24 | | | |
NCT06503159: Hippocampal Network Changes Following Mindfulness Training in Tobacco Vaping Adolescents in an Open-label, Pilot Study |
|
|
| Recruiting | N/A | 120 | US | Mindfulness-based Stress Reduction (MBSR) Program | National Institute on Drug Abuse (NIDA) | Vaping Teens, Healthy Volunteers | 06/26 | 06/26 | | |
NCT03427424: Imaging Biomarker for Addiction Treatment Outcome |
|
|
| Terminated | N/A | 52 | US | | National Institute on Drug Abuse (NIDA) | Opioid-Related Disorders, Alcohol-Related Disorders | 04/24 | 04/24 | | |
NCT05538910: Defining Neurobiological Links Between Substance Use and Mental Illness |
|
|
| Recruiting | N/A | 420 | US | Placebo Nicotine Patch, Nicotine Patch | National Institute on Drug Abuse (NIDA) | Major Depressive Disorder, Substance Use Disorder, Normal Physiology | 12/27 | 12/27 | | |
NCT05630781: Orexin s Role in the Neurobiology of Substance Use Disorder |
|
|
| Recruiting | N/A | 140 | US | Belsomra, Placebo, Methylphenidate | National Institute on Drug Abuse (NIDA) | Nicotine Dependence | 12/27 | 12/27 | | |
NCT01036581: Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging |
|
|
| Recruiting | N/A | 1000 | US | MagPro X100 Magnetic Stimulator, Transcranial Rotating Magnetic Stimulator, Magnetom Prisma Fit 3T Scanner | National Institute on Drug Abuse (NIDA) | Drug Abuse, Nicotine Dependence | 12/29 | 12/29 | | |
| Hardy, Nancy M |
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation |
|
|
| Terminated | 3 | 130 | US | AB-205, E-CEL cells, Placebo | Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM) | Hodgkin Lymphoma, Non Hodgkin Lymphoma | 12/23 | 01/25 | | |
ACCESS, NCT04904588: HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide |
|
|
| Recruiting | 2 | 300 | US | Busulfan, Busulfex®, Fludarabine, Fludara®, Total-body irradiation, TBI, Cyclophosphamide, Cytoxan®, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), PBSC HSCT, PBSC HCT, PBSC Transplantation, Bone Marrow Hematopoietic Stem Cell Transplantation, BM HSCT, BM HCT, Bone Marrow Transplantation, Post-transplant Cyclophosphamide, Mesna, Mesnex®, Tacrolimus, Mycophenolate Mofetil, MMF, Cellcept®, Patient-Reported Outcomes | Center for International Blood and Marrow Transplant Research, National Marrow Donor Program | Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma | 07/24 | 07/24 | | |
| Recruiting | 2 | 110 | US | zamtocabtagene autoleucel (MB-CART2019.1), Cyclophosphamide, Fludarabine, Bendamustine | Miltenyi Biomedicine GmbH | Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma | 12/24 | 12/26 | | |
| Recruiting | 1 | 75 | US | CNTY-101, IL-2, Lymphodepleting Chemotherapy | Century Therapeutics, Inc. | R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma | 08/25 | 08/27 | | |
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients |
|
|
| Available | N/A | | Canada, US, RoW | CTL019, tisagenlecleucel, Kymriah | Novartis Pharmaceuticals | Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL) | | | | |
NCT06116110: Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU |
|
|
| Not yet recruiting | N/A | 150 | US | Long-term Follow-Up | Miltenyi Biomedicine GmbH | Non Hodgkin Lymphoma | 12/39 | 12/39 | | |
NCT05768269: A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product |
|
|
| Recruiting | N/A | 375 | US | No Intervention | Century Therapeutics, Inc. | Hematological Malignancy, Solid Tumor Malignancy | 03/40 | 03/40 | | |
| Iacono, Aldo T |
NCT04415476: Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS) |
|
|
| Withdrawn | 2 | 30 | NA | Assigned Interventions, Tacrolimus, Mycophenolate mofetil, Prednisone, Sirolimus, Prograft, Cellcept, Deltasone, Prednicot, Rayos, Sterapred, Rapamune | University of Maryland, Baltimore | Disorder Related to Lung Transplantation, Chronic Rejection of Lung Transplant, Decreased Immunologic Activity | 06/24 | 06/28 | | |
